Jonathan Fialkow, MD
Cardiovascular Disease · Miami, FLNPI 1538176557
Payments from drug & device makers
Across 475 payments — averaging $5371.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- OPKO Pharmaceuticals, LLC$1.1M
- Amgen$1M
- AstraZeneca$115K
- Novartis$91K
- Amarin Pharma, Inc.$71K
- Astrazeneca UK Limited$56K
- plus $107K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| OPKO Pharmaceuticals, LLC | 20 | $1,081,524 |
| Amgen | 68 | $1,030,124 |
| AstraZeneca | 7 | $114,544 |
| Novartis | 12 | $90,886 |
| Amarin Pharma, Inc. | 59 | $71,441 |
| Astrazeneca UK Limited | 4 | $56,239 |
| Cleerly, Inc. | 19 | $54,639 |
| Esperion Therapeutics, Inc. | 25 | $27,135 |
| Novo Nordisk AS | 177 | $9,650 |
| Medtronic(2 entities) | 39 | $4,173 |
| Pfizer | 3 | $3,530 |
| Novo Nordisk | 8 | $3,487 |
| Boehringer Ingelheim International GmbH | 5 | $2,270 |
| Boston Scientific | 5 | $367 |
| Braemar Manufacturing, LLC | 1 | $294 |
| Lilly USA, LLC | 3 | $246 |
| Impulse Dynamics (USA) Inc. | 3 | $211 |
| Philips North America LLC | 1 | $174 |
| Heartflow, Inc. | 1 | $164 |
| Itamar Medical Inc | 1 | $125 |
| Gilead | 4 | $69 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Current Health, Inc. | 1 | $25 |
| Abbott | 1 | $22 |
| Bayer | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
How this compares
$2,551,470 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Miami
- Melvin Martinez-CastrillonMiami$1.6M
- Theodore FeldmanMiami$637K
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.